TERT promoter mutations (56.1%) are frequent in glioblastoma or, when concurrent with IDH mutation and 1p/19q co-deletion, which is not clinically available on FoundationOne CDx, point to oligodendroglioma. This evidence concerns the gene IDH2 and oligodendroglioma.